MAP Kinase Kinase 2, antagonists & inhibitors
DBCAT001917Pharmacologic class
A DrugBank category of 2 drugs. 2 of them are approved.
What you can answer from here — as of February 03, 2021
Which targets do MAP Kinase Kinase 2, antagonists & inhibitors share, and which companies have late-stage candidates in this class?
Create a free account or log in to explore the full data card.
Create Account